Product Description: Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23./[2]de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
CAS Number: 945721-28-8
Molecular Weight: N/A
Compound Purity: 99.00
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: ADC Antibody;CD38
English
Deutsch
